Surgical Management of Complications after Dexamethasone Implant Injection

Published on May 15, 2021in Journal of The Korean Ophthalmological Society
· DOI :10.3341/JKOS.2021.62.5.631
So Hee Kim1
Estimated H-index: 1
,
Youna Choi + 4 AuthorsSung Who Park11
Estimated H-index: 11
Source
Abstract
References0
Newest
#1Wungrak Choi (Yonsei University)H-Index: 9
#2Sung Eun Park (Yonsei University)H-Index: 2
Last. Min Kim (Yonsei University)H-Index: 18
view all 10 authors...
Background/Aims To analyse intraocular pressure (IOP) changes over a period of 1 year after intravitreal dexamethasone (DEX, Ozurdex) implant injection and to compare the results with those of previously published studies that involved non-Asian populations. Methods A retrospective observational study was conducted. A total of 540 eyes of 503 patients who received DEX implant injection and were diagnosed with macular oedema (ME) due to various retinal diseases were examined. IOP was measured pri...
11 CitationsSource
#1Claudio Furino (University of Bari)H-Index: 16
#2Nicola Recchimurzo (University of Bari)H-Index: 10
Last. Giovanni Alessio (University of Bari)H-Index: 15
view all 4 authors...
To study if cauterization of the scleroconjuctival wound secondary to intravitreal dexamethasone implant in vitrectomized eyes is effective to avoid scleral leakage and hypotony.A total of 35 vitrectomized eyes of 35 consecutive patients with macular edema who underwent a single intravitreal dexamethasone implant injection in the operating room at the Eye Clinic of the University of Bari, Italy, from 2013 to 2017 were retrospectively reviewed. At the end of the injection, transconjuctival/sclera...
1 CitationsSource
#1S. K. MishraH-Index: 1
#2Ankur GuptaH-Index: 23
Last. Vineet SharmaH-Index: 22
view all 7 authors...
Among the retinal vascular diseases, burden of retinal vein occlusion is most common immediately after diabetic retinopathy. Intravitreal corticosteroids are gaining popularity in managing macular edema (ME) of RVO. Our study compares efficacy and safety of intravitreal triamcinolone (IVTA) and dexamethasone implant (IVD) over 6 months. This comparative, prospective, randomized study on 40 patients of non-ischemic central RVO with significant ME (> 330 μm) of 35 mmHg and 66% needed combination t...
6 CitationsSource
#1Eric K. Chin (Queen's University)H-Index: 14
#2David R.P. AlmeidaH-Index: 12
Last. Vinit B. MahajanH-Index: 32
view all 14 authors...
To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s). Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of ≥30 mmHg or an increase of ≥10 mmHg from baseline. Ninety-four inj...
17 CitationsSource
#1Ronakorn Panjaphongse (UCSF: University of California, San Francisco)H-Index: 2
#2Jay M. Stewart (UCSF: University of California, San Francisco)H-Index: 21
Ozurdex is a preloaded, injectable intravitreal dexamethasone delivery system with a 22-gauge needle.1,2 We describe risk factors in 2 patients who developed a transient decrease in intraocular pre...
2 CitationsSource
#1David S. BoyerH-Index: 58
#2Young Hee Yoon (Asan Medical Center)H-Index: 30
Last. Scott M. Whitcup (Allergan)H-Index: 25
view all 10 authors...
Purpose To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex, DEX implant) 0.7 and 0.35 mg in the treatment of patients with diabetic macular edema (DME). Design Two randomized, multicenter, masked, sham-controlled, phase III clinical trials with identical protocols were conducted. Data were pooled for analysis. Participants Patients (n = 1048) with DME, best-corrected visual acuity (BCVA) of 20/50 to 20/200 Snellen equivalent, and central retinal thickness (CRT) of...
535 CitationsSource
#1Rahul N. Khurana (UCSF: University of California, San Francisco)H-Index: 19
#1Rahul N. Khurana (UCSF: University of California, San Francisco)H-Index: 9
Last. Steven Yeh (Emory University)H-Index: 33
view all 8 authors...
Objective To describe the risk factors, clinical course, and complications of migration of a dexamethasone (DEX) intravitreal implant (OZURDEX; Allergan, Inc., Irvine, CA) into the anterior chamber and subsequent management strategies. Design Retrospective, observational case series. Participants Fifteen patients had 18 episodes of migration of the DEX implant into the anterior chamber. Methods The medical records of 15 patients with spontaneous migration of a DEX implant were retrospectively re...
95 CitationsSource
#1Armin R. Afshar (UCSF: University of California, San Francisco)H-Index: 12
#2Allison R. Loh (UCSF: University of California, San Francisco)H-Index: 9
Last. Jay M. Stewart (UCSF: University of California, San Francisco)H-Index: 21
view all 5 authors...
10 CitationsSource
Dear Editor, Ozurdex® (Allergan Inc., Irvine, CA, USA) is an intravitreal implant containing the dexamethasone. It uses NOVADUR® drug delivery technology, in which a biodegradable material is combined with the active drug dexamethasone to form a small rod-shaped implant of 0.46 mm in diameter and 6 mm in length. Inside the eye, the implant is progressively dissolved in the vitreous gel, as it slowly releases dexamethasone (0.7 mg). This biodegradable device is indicated for the treatment of macu...
63 CitationsSource
#1Julia A. Haller (Wills Eye Institute)H-Index: 60
#2Francesco BandelloH-Index: 64
Last. Scott M. Whitcup (Allergan)H-Index: 25
view all 11 authors...
Objective To evaluate the safety and efficacy of 1 or 2 treatments with dexamethasone intravitreal implant (DEX implant) over 12 months in eyes with macular edema owing to branch or central retinal vein occlusion (BRVO or CRVO). Design Two identical, multicenter, prospective studies included a randomized, 6-month, double-masked, sham-controlled phase followed by a 6-month open-label extension. Participants We included 1256 patients with vision loss owing to macular edema associated with BRVO or ...
455 CitationsSource
Cited By0
Newest